Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 4.39% | 14.62% | |||
| Gross Profit | -4.39% | -14.62% | |||
| SG&A Expenses | 7.78% | -13.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.16% | 6.62% | |||
| Operating Income | -5.16% | -6.62% | |||
| Income Before Tax | -10.18% | -8.33% | |||
| Income Tax Expenses | -1,102.50% | 3.90% | |||
| Earnings from Continuing Operations | -4.61% | -8.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.61% | -8.40% | |||
| EBIT | -5.16% | -6.62% | |||
| EBITDA | -5.26% | -6.67% | |||
| EPS Basic | -4.00% | -8.05% | |||
| Normalized Basic EPS | -9.52% | -7.98% | |||
| EPS Diluted | -4.00% | -8.05% | |||
| Normalized Diluted EPS | -9.52% | -7.98% | |||
| Average Basic Shares Outstanding | 0.59% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.59% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||